Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study
- PMID: 20858492
- DOI: 10.1053/j.gastro.2010.09.038
Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study
Abstract
Background & aims: Prevalence of nonalcoholic fatty liver disease (NAFLD) has not been well established. The purpose of this study was to prospectively define the prevalence of both NAFLD and nonalcoholic steatohepatitis (NASH).
Methods: Outpatients 18 to 70 years old were recruited from Brooke Army Medical Center. All patients completed a baseline questionnaire and ultrasound. If fatty liver was identified, then laboratory data and a liver biopsy were obtained.
Results: Four hundred patients were enrolled. Three hundred and twenty-eight patients completed the questionnaire and ultrasound. Mean age (range, 28-70 years) was 54.6 years (7.35); 62.5% Caucasian, 22% Hispanic, and 11.3% African American; 50.9% female; mean body mass index (BMI) (calculated as kg/m(2)) was 29.8 (5.64); and diabetes and hypertension prevalence 16.5% and 49.7%, respectively. Prevalence of NAFLD was 46%. NASH was confirmed in 40 patients (12.2% of total cohort, 29.9% of ultrasound positive patients). Hispanics had the highest prevalence of NAFLD (58.3%), then Caucasians (44.4%) and African Americans (35.1%). NAFLD patients were more likely to be male (58.9%), older (P = .004), hypertensive (P < .00005), and diabetic (P < .00005). They had a higher BMI (P < .0005), ate fast food more often (P = .049), and exercised less (P = 0.02) than their non-NAFLD counterparts. Hispanics had a higher prevalence of NASH compared with Caucasians (19.4% vs 9.8%; P = .03). Alanine aminotransferase, aspartate aminotransferase, BMI, insulin, Quantitative Insulin-Sensitivity Check Index, and cytokeratin-18 correlated with NASH. Among the 54 diabetic patients, NAFLD was found in 74% and NASH in 22.2%.
Conclusion: Prevalence of NAFLD and NASH is higher than estimated previously. Hispanics and patients with diabetes are at greatest risk for both NAFLD and NASH.
Trial registration: ClinicalTrials.gov NCT01100398.
Copyright © 2011 AGA Institute. Published by Elsevier Inc. All rights reserved.
Comment in
-
Fibrosing NASH: on being a blind man in a dark room looking for a black cat (that isn't there).Gastroenterology. 2011 Jan;140(1):25-8. doi: 10.1053/j.gastro.2010.11.027. Epub 2010 Nov 24. Gastroenterology. 2011. PMID: 21110967 No abstract available.
Similar articles
-
Prevalence of non alcoholic fatty liver and Non alcoholic Steatohepatitis in Peshawar Cantonment, Khyber Pakhtunkhwa, Pakistan.Pak J Pharm Sci. 2018 Jan;31(1):193-198. Pak J Pharm Sci. 2018. PMID: 29348103
-
Non alcoholic fatty liver disease (NAFLD) in a Sudanese population: What is the prevalence and risk factors?Arab J Gastroenterol. 2014 Mar;15(1):12-5. doi: 10.1016/j.ajg.2014.01.008. Epub 2014 Feb 12. Arab J Gastroenterol. 2014. PMID: 24630507
-
Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors.Liver Int. 2011 May;31(5):700-6. doi: 10.1111/j.1478-3231.2011.02482.x. Epub 2011 Feb 20. Liver Int. 2011. PMID: 21457442
-
Nonalcoholic fatty liver disease: defining a common problem.Eur Rev Med Pharmacol Sci. 2005 Sep-Oct;9(5):253-9. Eur Rev Med Pharmacol Sci. 2005. PMID: 16231586 Review.
-
Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations.Am J Gastroenterol. 2021 Feb 1;116(2):254-262. doi: 10.14309/ajg.0000000000001054. Am J Gastroenterol. 2021. PMID: 33284184 Review.
Cited by
-
Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease.Aliment Pharmacol Ther. 2024 Jun;59 Suppl 1(Suppl 1):S41-S51. doi: 10.1111/apt.17752. Aliment Pharmacol Ther. 2024. PMID: 38813822 Review.
-
H2FPEF Scores Are Increased in Patients with NASH Cirrhosis and Are Associated with Post-liver Transplant Heart Failure.Dig Dis Sci. 2024 May 23. doi: 10.1007/s10620-024-08438-1. Online ahead of print. Dig Dis Sci. 2024. PMID: 38782854
-
The health care experience of adults with metabolic dysfunction-associated steatohepatitis and influence of PNPLA3: A qualitative study.Hepatol Commun. 2024 May 22;8(6):e0451. doi: 10.1097/HC9.0000000000000451. eCollection 2024 Jun 1. Hepatol Commun. 2024. PMID: 38780312 Free PMC article.
-
Lipoprotein subclasses are associated with Hepatic steatosis: insights from the prospective multicenter imaging study for the evaluation of chest pain (PROMISE) clinical trial.Am J Prev Cardiol. 2024 May 5;18:100680. doi: 10.1016/j.ajpc.2024.100680. eCollection 2024 Jun. Am J Prev Cardiol. 2024. PMID: 38764778 Free PMC article.
-
Future therapeutic perspectives in nonalcoholic fatty liver disease: a focus on nuclear receptors, a promising therapeutic target.Med Pharm Rep. 2024 Apr;97(2):111-119. doi: 10.15386/mpr-2628. Epub 2024 Apr 25. Med Pharm Rep. 2024. PMID: 38746033 Free PMC article. Review.
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials